Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy

Arthritis and Rheumatology

Volumn 69, Issue 10, 2017, Pages 1960-1968

  Winthrop, Kevin L ^a   Curtis, Jeffrey R ^b   Lindsey, Stephen ^c   Tanaka, Yoshiya ^d   Yamaoka, Kunihiro ^e   Valdez, Hernan ^f   Hirose, Tomohiro ^f   Nduaka, Chudy I ^f   Wang, Lisy ^f   Mendelsohn, Alan M ^f   Fan, Haiyun ^f   Chen, Connie ^f   Bananis, Eustratios ^f  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Ochsner Health Center   (United States)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHLOROQUINE; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; PLACEBO; TOFACITINIB; ANTIRHEUMATIC AGENT; ISOXAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL OUTCOME; COMPARATIVE STUDY; CONTROLLED STUDY; DERMATOME; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG MEGADOSE; DRUG WITHDRAWAL; EASTERN EUROPE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; JAPAN; KOREA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DOSE RESPONSE; FACTUAL DATABASE; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHLOROQUINE; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HERPES ZOSTER; HUMANS; INCIDENCE; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIPERIDINES; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RISK FACTORS;

EID: 85028916794     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40189     Document Type: Article

References (56)

1. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008;57(RR–5):1–30.
2. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350–4.
3. Watson PN. Postherpetic neuralgia. BMJ Clin Evid 2010;2010.
4. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431–8.
5. Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol 2016;68:2328–37.
6. Yun H, Xie F, Delzell E, Chen L, Levitan EB, Lewis JD, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) 2015;67:731–6.
7. Pappas DA, Hooper MM, Kremer JM, Reed G, Shan Y, Wenkert D, et al. Herpes zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res (Hoboken) 2015;67:1671–8.
8. Winthrop K, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2675–84.
9. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243–52.
10. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 2017;76:1253–62.
11. Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, et al. Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 2015;74:2107–16.
12. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009;301:737–44.
13. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: systematic review and meta-analysis. Joint Bone Spine 2014;81:215–21.
14. Zhang N, Wilkinson S, Riaz M, Ostor AJ, Nisar MK. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review. Clin Exp Rheumatol 2012;30:962–71.
15. Cook IF. Herpes zoster in children following malaria. J Trop Med Hyg 1985;88:261–4.
16. Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol 2015;67:616–25.
17. Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony H, Lee SK, et al. Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial. Arthritis Res Ther 2015;17:95.
18. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo [published erratum appears in Arthritis Rheum 2012;64:1487]. Arthritis Rheum 2009;60:1895–905.
19. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 2012;64:970–81.
20. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617–29.
21. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150–8.
22. Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 2015;25:514–21.
23. Conaghan PG, Østergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, et al. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis 2016;75:1024–33.
24. Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015;74:1311–6.
25. McInnes IB, Kim HY, Lee SH, Mandel D, Song YW, Connell CA, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2014;73:124–31.
26. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451–60.
27. Van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four–month phase III randomized radiographic study. Arthritis Rheum 2013;65:559–70.
28. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495–507.
29. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253–61.
30. Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508–19.
31. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377–86.
32. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 2014;41:837–52.
33. Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016;75:687–95.
34. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
35. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
36. Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 2013;65:854–61.
37. Shalom G, Zisman D, Bitterman H, Harman-Boehm I, Greenberg-Dotan S, Dreiher J, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatol 2015;151:533–8.
38. Zisman D, Bitterman H, Shalom G, Feldhamer I, Comanesther D, Batat E, et al. Psoriatic arthritis treatment and the risk of herpes zoster. Ann Rheum Dis 2016;75:131–5.
39. Malmgaard L. Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res 2004;24:439–54.
40. Meyer D, Head R, Thompson J, Ghosh S, LaBranche T, Storer C, et al. Mechanism of action of the JAK inhibitor, CP-690550, in rheumatoid arthritis. Presented at the 8th Cytokines and Inflammation Conference; 2010 January 28; San Diego, California.
41. Konig N, Fiehn C, Wolf C, Schuster M, Cura Costa E, Tungler V, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis 2017;76:468–72.
42. Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2016;75:1909–16.
43. Narain S, Furie R. Update on clinical trials in systemic lupus erythematosus. Curr Opin Rheumatol 2016;28:477–87.
44. McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 2012;64:3666–76.
45. De Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ, et al. Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab. Arthritis Res Ther 2015;17:78.
46. Haroon N, Srivastava R, Misra R, Aggarwal A. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression. J Rheumatol 2008;35:975–8.
47. Bing N, Zhou H, Zhang B, Bradley JD, Nagaoka M, Valdez H, et al. Genome-wide trans-ancestry meta-analysis of herpes zoster in RA and Pso patients treated with tofacitinib [abstract]. Arthritis Rheumatol 2015;67 Suppl 10. URL: http://acrabstracts.org/abstract/genome-wide-trans-ancestry-meta-analysis-of-herpes-zoster-in-ra-and-pso-patients-treated-with-tofacitinib/.
48. Takao Y, Miyazaki Y, Okeda M, Onishi F, Yano S, Gomi Y, et al. Incidences of herpes zoster and postherpetic neuralgia in Japanese adults aged 50 years and older from a community-based prospective cohort study: the SHEZ study. J Epidemiol 2015;25:617–25.
49. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308:43–9.
50. Winthrop K, Wouters A, Choy E, Soma K, Hodge J, Nduaka C, et al. Assessment of immunogenicity of live zoster vaccination (Zostavax®) in rheumatoid arthritis patients on background methotrexate before and after initiating tofacitinib or placebo [abstract]. Arthritis Rheumatol 2015;67 Suppl 10. URL: http://acrabstracts.org/abstract/assessment-of-immunogenicity-of-live-zoster-vaccination-zostavax-in-rheumatoid-arthritis-patients-on-background-methotrexate-before-and-after-initiating-tofacitinib-or-placebo/.
51. Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, et al. Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to cDMARD therapy: results of the phase 3 RA-BUILD study. Ann Rheum Dis 2015;74 Suppl 2:79.
52. XELJANZ prescribing information. New York: Pfizer; 2016. URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=959.
53. Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Mansfield K, et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology 2016;87:94–102.
54. Bidkar M, Vassallo R, Luckey D, Smart M, Mouapi K, Taneja V. Cigarette smoke induces immune responses to vimentin in both, arthritis-susceptible and -resistant humanized mice. PLoS One 2016;11:e0162341.
55. Chan AY, Conrady CD, Ding K, Dvorak JD, Stone DU. Factors associated with age of onset of herpes zoster ophthalmicus. Cornea 2015;34:535–40.
56. Fleischmann R, Charles-Schoeman C, Burmester G, Zerbini C, Nash P, Kwok K, et al. The effects of glucocorticoids on the efficacy of tofacitinib as monotherapy and in combination therapy with nonbiologic Dmards: an analysis of data from six phase 3 studies [abstract]. Arthritis Rheumatol 2015;67 Suppl 10. URL: http://acrabstracts.org/abstract/the-effects-of-glucocorticoids-on-the-efficacy-of-tofacitinib-as-monotherapy-and-in-combination-therapy-with-nonbiologic-dmards-an-analysis-of-data-from-six-phase-3-studies/.